is gone fishing
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ORRV Growing wings now!
ORRV No worries! Plenty of .002s up for sale tommorow before Tues./Wed. updates sent us to mulptiple pennies.
ORRV In @ 5... Luv Big Red Flag Merger Plays! Big money to be made down here!
Thanx for the heads up! GLTU
Happy Holidays to everyone!
Thanks! Never know down here. Could be a home run.
TXTM Looks like we have MJ coming into play here...
December 8, 2016
Plandai Biotechnology, Inc. Announces South African Department of Health Endorses Access to Medicinal Cannabis
Roger Baylis-Duffield,
Chairman and Chief Executive Officer of Plandaí Biotechnology, stated, "We are pleased to see this change in the department's stance on medical cannabis and are looking forward to producing and testing our Phytofare® cannabinoid complex in the near future in South Africa.
http://www.nasdaq.com/press-release/plandai-biotechnology-inc-announces-south-african-department-of-health-endorses-access-to-medicina-20161208-00205
TXTM That's right...December 8, 2016
Plandai Biotechnology, Inc. Announces South African Department of Health Endorses Access to Medicinal Cannabis
Roger Baylis-Duffield,
Chairman and Chief Executive Officer of Plandaí Biotechnology, stated, "We are pleased to see this change in the department's stance on medical cannabis and are looking forward to producing and testing our Phytofare® cannabinoid complex in the near future in South Africa.
http://www.nasdaq.com/press-release/plandai-biotechnology-inc-announces-south-african-department-of-health-endorses-access-to-medicina-20161208-00205
TXTM Great post!... BIG DD TXTM ACQUISTION
Here is more information to catch everyone up to speed.
PROTEXT MOBILITY INC. ACQUISTION NEW 8-K
News Out!!!...The company is pleased to announced that it has reached an agreement to acquire Plandai Biotechnology South Africa (Plandai SA), a wholly owned subsidiary of Plandai Biotechnolgy, Inc (PLPL). Plandai SA is a biotechnology firm engaged in the research and development of botanical extracts, aimed at treating metabolic disorders, like diabetes & others. The parent company, Plandaí Biotechnology, Inc. is the culmination of over 10 years of R&D in the field of plant extracts with principle holdings including raw materials processing infrastructure, production facilities, farms and land totaling more than 7500 acres, in the province of Mpumalanga, South Africa.
Closing is expected to occur on or around January 2, 2017.
Additional Information about Plandai Biotechnolgy, Inc
Plandaí Biotechnology, Inc. and its subsidiaries develop highly bioavailable extracts. It controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing its proprietary Phytofare® extracts in-house, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company's products include cosmeceutical, wellness, anti-aging, pharmaceutical and animal husbandry.
MJ Research Endorsement in South Africa
December 8, 2016
Plandai Biotechnology, Inc. Announces South African Department of Health Endorses Access to Medicinal Cannabis
Roger Baylis-Duffield,
Chairman and Chief Executive Officer of Plandaí Biotechnology, stated, "We are pleased to see this change in the department's stance on medical cannabis and are looking forward to producing and testing our Phytofare® cannabinoid complex in the near future in South Africa.
Phytofare Technology and Exclusive Rights
Plandai Biotechnology, Inc., a producer of highly bioavailable plant extracts for industries including health, wellness, nutriceutical, and pharmaceutical, today announced that it has signed an exclusive agreement with North-West University in Potchefstroom, South Africa, that holds the patents and associated intellectual property associated with the entrapment of compounds in long-chain fatty acids-based nano- and micro-particles, known as Pheroid(R). Under the terms of the world license, Plandai has the exclusive right to use the Pheroid(R) technology with all Phytofare polyene-based extracts, which includes proprietary extracts of most botanical matter, for human and animal use.
The Pheroid(R) technology, developed for a number of applications by Professors Anne Grobler Awie Kotze and Jeanetta du Plessis of North-West University, allows particles to be encapsulated, or entrapped, in different media that can improve absorption through protecting the contents. It is actively used worldwide for industrial and agricultural purposes and has been extensively tested in humans and animals by Professor Grobler where it has shown an ability to significantly increase the level of absorption of the entrapped particles into the bloodstream.
For Plandai's purposes, the technology will enable the company to produce Phytofare topical products with significantly enhanced tissue absorption and oral products that can help Phytofare survive intact on its passage through the digestive tract and into the bloodstream. Once in the bloodstream, human cells perceive the Pheroid(R) material as a biological building block and as a source of energy, allowing them to pass through the cell membrane and, by metabolism of the long chain fatty acids, release the valuable phytonutrients directly to the tissues.
Plandai and FDA have existing relationship
links
https://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=11750245
http://www.protextm.co
http://www.nasdaq.com/press-release/plandai-biotechnology-inc-announces-south-african-department-of-health-endorses-access-to-medicina-20161208-00205
https://www.accesswire.com/407406/Plandai-Biotechnology-Inc-Announces-License-Agreement-to-Acquire-Nano-and-Micro-Entrapment-Technology
http://www.nutraingredients-usa.com/Manufacturers/FDA-exemption-speeds-release-of-Plandai-s-catechin-supplement
This is just the start to the digging. TXTM
PMEA Agree! Let em out here. Party has just begun!
TXTM Most players on vacation. Check back in January when the heard is back in full force & details of the Plandai deal is announced. Till then...Happy Holidays to everyone!
Full day today...Closed on monday to observe x-mas. Here...keep this link for the future... http://www.money-zine.com/investing/stocks/stock-market-holidays/
That's not true... PLPL is trading @ .0248 right now...
http://www.otcmarkets.com/stock/PLPL/profile
That was the plan in Sept. & now it's coming together. Greener days ahead as this story unfolds.
TXTM Stick around JAN 2nd is not far away...
Item 8.01 Other Events.
The company has reached an agreement to acquire Plandai Biotechnology South Africa (Plandai SA), a wholly owned subsidiary of Plandai Biotechnolgy, Inc. Plandai SA is a biotechnology firm engaged in the research and development of botanical extracts, aimed at treating metabolic disorders, like diabetes & others. Closing is expected to occur on or around January 2nd, 2017.
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=11750245
Cannabis Biosciences is the parent company of Plandaí Biotechnology Uruguay, S.A., and holds the license from Plandaí to conduct all product development, clinical trials, sales and marketing for Plandaí’s cannabis-derived bioavailable extract.
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=11601159
Welcome to amateur hour in the otc!
TXTM Weak hands out. 6s up & thin!
TXTM 8K out today... http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=11750245
TXTM (.0004) Let the chase begin... The company is pleased to announced that it has reached an agreement to acquire Plandai Biotechnology South Africa (Plandai SA), a wholly owned subsidiary of Plandai Biotechnolgy, Inc (PLPL). Plandai SA is a biotechnology firm engaged in the research and development of botanical extracts, aimed at treating metabolic disorders, like diabetes & others. The parent company, Plandaí Biotechnology, Inc. is the culmination of over 10 years of R&D in the field of plant extracts with principle holdings including raw materials processing infrastructure, production facilities, farms and land totaling more than 7500 acres, in the province of Mpumalanga, South Africa.
Closing is expected to occur on or around January 2, 2017.
http://www.protextm.co/
TXTM Gonna be a heck of a Friday... The company is pleased to announced that it has reached an agreement to acquire Plandai Biotechnology South Africa (Plandai SA), a wholly owned subsidiary of Plandai Biotechnolgy, Inc (PLPL). Plandai SA is a biotechnology firm engaged in the research and development of botanical extracts, aimed at treating metabolic disorders, like diabetes & others. The parent company, Plandaí Biotechnology, Inc. is the culmination of over 10 years of R&D in the field of plant extracts with principle holdings including raw materials processing infrastructure, production facilities, farms and land totaling more than 7500 acres, in the province of Mpumalanga, South Africa.
Closing is expected to occur on or around January 2, 2017.
http://www.protextm.co/
TXTM over 18 million sitting @ 4 waiting for a nervous nellie or some day trader wacks!
TXTM Agree! Buying & holding...
http://ih.advfn.com/stock-market/USOTC/protext-mobility-inc-TXTM/trades
PLAD (.043) Nice move .0135>>>.06 today Congrats! PLAD on watch Thanks for sharing!
TXTM (.0005) New site goes live in 25 hrs... http://www.protextm.co/
TXTM Something Big brewing here... The Company has entered into a letter of intent with a publicly traded company to acquire a wholly owned subsidiary. The parties look to close definitive documents around year end.
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=11733213
TXTM 12 million just slapped the 4s! Wilson!
TXTM Sure is! 4s on deck.
TXTM 3s getting slammed! Just updated some info... http://www.otcmarkets.com/stock/TXTM/profile
TXTM Just updated company profile... http://www.otcmarkets.com/stock/TXTM/profile
Text of the New Rule Regarding CBD from the DEA
Here’s the text of the new rule:
“Final Action
After careful consideration of all comments, the DEA is hereby amending 21 CFR 1308.11(d) to include a new subparagraph (58) which creates a new code number in Schedule I as follows:
“(58) Marihuana Extract—7350
“Meaning an extract containing one or more cannabinoids that has been derived from any plant of the genus Cannabis, other than the separated resin (whether crude or purified) obtained from the plant.”
The creation of this new drug code in the DEA regulations for marihuana extracts allows for more appropriate accounting of such materials consistent with treaty provisions. Such marihuana Start Printed Page 90196extracts remain in Schedule I. Entities registered to handle marihuana (under drug code 7360) that also handle marihuana extracts, will need to apply to modify their registrations to add the new drug code 7350 to their existing DEA registrations and procure quotas specifically for drug code 7350 each year.”
CBD Ban Won’t Happen Without a Big Fight
This strange new DEA rule is going against the tide of the recent movement to legalize marijuana or cannabis, as was evidenced in the recent November 2016 elections where California, Maine, Massachusetts and other states voted to make it recreationally or medically legal. You can be sure that many cannabis lawyers, businesses and consumers are going to do their utmost to stop governmental overreach and prevent a CBD ban from occurring.
http://freedom-articles.toolsforfreedom.com/cbd-ban-dea-reclassification-schedule-1/
VCEL Nice dip below 4.00 Cmon back to hod by eod!
TXTM Waiting for a follow up PR giving us details about the 8K filed yesterday. Big loading going on here while we wait.
LOL One newbies trash is a seasoned traders Treasure!
Yup! HUGE buys down here. This is getting exciting!
TXTM Market loaded those wacks! Maybe DAwar newbie is gone now.
Lol Maybe they hope TXTM will merge with these guys...
3-D Matrix Ltd
7777:TYO
http://markets.ft.com/data/equities/tearsheet/summary?s=7777:TYO
VCEL With todays vol. hope to see a solid play. 6.69 52 wk high!
VCEL (4.22) Huge news... CAMBRIDGE, Mass., Dec. 14, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today announced that the U.S. Food and Drug Administration (FDA) has approved MACI® (autologous cultured chondrocytes on porcine collagen membrane) for the repair of symptomatic single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults.
"The treatment of articular cartilage defects in the knee is challenging because articular cartilage in adults has minimal capacity to repair itself," said David Recker
, MD, chief medical officer of Vericel. "While orthopedic surgeons have long understood that autologous chondrocyte implantation can regenerate cartilage tissue, the previous surgical procedure was technically complex and time consuming, and the indicated patient population was limited. MACI is the first product to show a statistically significantly greater improvement in KOOS pain and function scores compared to microfracture, a commonly performed alternative surgical treatment for cartilage repair, in a well-controlled Phase 3 clinical study. With the introduction of MACI, orthopedic surgeons will have a simplified treatment option available for a broader patient population supported by solid clinical evidence."
The approval of MACI is based on the SUMMIT study (Superiority of MACI implant versus Microfracture Treatment in patients with symptomatic articular cartilage defects in the knee), a two-year prospective, multicenter, randomized, open-label, parallel-group study which demonstrated a statistically significantly (p=0.001) greater improvement in KOOS pain and function (SRA) scores in the MACI group compared to the microfracture group at two years. Patients from the two-year SUMMIT study had the option to enroll in a three-year follow-up study (extension study). A majority of the patients who completed the SUMMIT study also participated in the extension study. Overall efficacy data support a long-term clinical benefit from the use of MACI in patients with cartilage defects of the knee.
MACI is the first FDA-approved cellularized scaffold product that applies tissue engineering processes to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee.
"Bringing an important new therapy to orthopedic surgeons and patients is a significant milestone for Vericel, and I would like to thank the FDA for working closely with us to make MACI available for these patients," said Nick Colangelo
, president and CEO of Vericel. "We believe that the introduction of MACI, along with investments to expand our commercial organization and implement new patient support programs, positions Vericel to generate significant growth in 2017 and beyond."
Conference Call Information
Today's conference call will be available live at 9:00am (EST) in the Investors section of the Vericel website at http://investors.vcel.com/events.cfm. Please access the site at least 15 minutes prior to the scheduled start time in order to download the required audio software if necessary. To participate in the live call by telephone, please call (877) 312-5881 and reference Vericel Corporation investor call. If calling from outside the U.S., please use the international phone number (253) 237-1173. If you are unable to participate in the live call, the webcast will be available until December 13, 2017. A replay of the call will also be available until 12:00pm (EDT) on December 18, 2016 by calling (855) 859-2056, or from outside the U.S. (404) 537-3406. The conference ID is 39558058.
http://www.nasdaq.com/press-release/fda-approves-maci-for-the-treatment-of-symptomatic-cartilage-defects-of-the-knee-in-adults-20161214-00189